In this article, we will look at the 10 Fast-Growing Small Cap Stocks to Buy According to Analysts.
On October 1, Francis Gannon, Co-Chief Investment Officer and Managing Director at Royce Investment Partners, released a report analyzing small-cap performance during the third quarter of 2025. During the third quarter, the highest returns were generated by the smallest stocks, as the Russell 2000 index gained 12.4%, outperforming the 8% gain of the Russell 1000 index. Notably, the micro-caps gained the most as the Russell Micro-cap Index rose 17% during the same time. Gannon attributed this long-overdue outperformance to lower rates and a resilient US economy.
Gannon highlighted that usually small-cap growth stocks do better than small-cap value stocks in the early part of a market upswing. However, in Q3 2025, the small-cap value stocks actually returned slightly more (12.6%) than small-cap growth stocks (12.2%). Looking at the returns from April 8, the small-cap growth rose 43.2%, outperforming the 35.3% rise of the small-cap value stocks.
In addition, on November 11, Lauren Romeo, CFA, Portfolio Manager, Principal at Royce Investment Partners, released another report discussing why high-quality small-caps may be poised to reassert leadership in the months. Endorsing the analysis of Gannon, Romeo noted that the initial rebound of the small-caps was led by low-quality/growth stocks. He highlighted that all previous small-cap leadership phases started in a similar fashion, with growth stocks taking the major share in the start, followed by higher-quality/ value companies taking over leadership in the longer term.
With that, let’s take a look at the 10 Fast-Growing Small Cap Stocks to Buy According to Analysts.
Stocks
Our Methodology
To curate the list of 10 Fast-Growing Small Cap Stocks to Buy According to Analysts, we used the Stock Analysis screener, Seeking Alpha, WSJ, CNN, and Insider Monkey’s Q2 2025 hedge funds database as our sources. Using the screener, we aggregated a list of small-cap stocks (Market Cap between $300 million and $2 billion) with at least 50% year-over-year revenue growth, 30% 3-year revenue growth, and more than 30% upside potential. After shortlisting the stocks that fit our criteria, we ranked the stocks in ascending order of the analysts’ upside potential. Lastly, we have also added hedge fund sentiment around each stock sourced from Insider Monkey’s database. Please note that the data was recorded on November 15, 2025.
Note: For the purpose of this article, we excluded clinical-stage companies from the list, focusing only on companies with organic revenue growth.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10 Fast-Growing Small Cap Stocks to Buy According to Analysts
10. Amprius Technologies, Inc. (NYSE:AMPX)
Market Capitalization: $1.47 billion
Year-over-year Revenue Growth: 234.14%
3-Year Revenue Growth: 129.48%
Number of Hedge Fund Holders: 11
Analyst Upside Potential: 37.29%
Amprius Technologies, Inc. (NYSE:AMPX) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 12, Amprius Technologies, Inc. (NYSE:AMPX) announced the establishment of Amprius Korea Battery Alliance to strengthen its global partnerships, increase its collaboration with supply chain partners, and diversify its manufacturing network.
This announcement comes at a critical time as the company’s total worldwide contract manufacturing capacity has exceeded 2 GWh. Management noted that the initial members of the alliance include suppliers, battery manufacturers, equipment makers, cell component producers, and important members from South Korea’s investment community.
Through this partnership, Amprius Technologies, Inc. (NYSE:AMPX) aims to advance its joint business development efforts, gain access to advanced technologies, and support the members of the industry through its technical and commercial efforts.
In addition to strengthening its global partnerships, Amprius Technologies, Inc. (NYSE:AMPX) on November 6, announced results for its fiscal Q3 2025. The company grew its revenue by 172.77% year-over-year to $21.43 million, surpassing estimates by $4.62 million. The EPS of negative $0.03 also topped the consensus by $0.03. Management attributed revenue growth to more than four times year-over-year growth in its second-generation SiCore battery shipments.
Following the release, on November 7, Ryan Pfingst from B. Riley Securities raised the firm’s price target on the stock from $11 to $16 and maintained a Buy rating.
Amprius Technologies, Inc. (NYSE:AMPX) develops, manufactures, and markets lithium-ion batteries for mobility applications, focusing on aviation, EVs, and LEVs.
9. Innodata Inc. (NASDAQ:INOD)
Market Capitalization: $1.82 billion
Year-over-year Revenue Growth: 73.57%
3-Year Revenue Growth: 44.57%
Number of Hedge Fund Holders: 16
Analyst Upside Potential: 44.21%
Innodata Inc. (NASDAQ:INOD) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 11, BWS Financial analyst Hamed Khorsand maintained a Buy rating on Innodata Inc. (NASDAQ:INOD) with a price target of $110. Earlier on November 7, George Sutton from Craig-Hallum had also maintained a Buy rating on the stock with a price target of $80.
The reiterated positive outlook follows the company’s fiscal Q3 2025 results, announced on November 6. The company grew its revenue by 19.77% to $62.55 million, surpassing estimates by $2.77 million. Moreover, the EPS of $0.24 also topped the consensus by $0.10. Management attributed the growth in revenue and increased profitability to its strategic focus on deepening its relationship with high-dollar value leading tech companies and AI innovation labs.
Notably, management highlighted optimism for further growth in 2026 by announcing verbal confirmations of deal expansion with its largest customer, which could potentially result in substantial revenue. It also announced another verbal confirmation of a deal with another big tech, which could result in $6.5 million annualized revenue run rate.
Hamed Khorsand of BWS Financial noted that the Q3 results depict the company’s ability to broaden its customer base effectively. He highlighted that the existing contracts of the company are expected to drive further revenue growth of at least 45%. Khorsand anticipates a 26% increase in 2026 revenue, considering the current growth trajectory of the company.
Innodata Inc. (NASDAQ:INOD) is a global data engineering company that provides services and platforms for AI data preparation, annotation, transformation, and model deployment.
8. Gevo, Inc. (NASDAQ:GEVO)
Market Capitalization: $477.35 million
Year-over-year Revenue Growth: 675.75%
3-Year Revenue Growth: 461.26%
Number of Hedge Fund Holders: 5
Analyst Upside Potential: 45.94%
Gevo, Inc. (NASDAQ:GEVO) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 11, Amit Dayal from H.C. Wainwright maintained a Buy rating on Gevo, Inc. (NASDAQ:GEVO) with a price target of $14. The rating follows the company’s fiscal Q3 2025 results, announced a day earlier, which exceeded expectations.
The company grew its revenue by 2,073.54% to $42.71 million, surpassing estimates by $11.34 million, along with an EPS of negative $0.03, exceeding expectations by $0.03. Management attributed the growth in revenue to $38.2 million from Gevo North Dakota, a $2 million increase in RNG and environmental attribute revenue, and $0.5 million in revenue from the sale of isooctane. The quarter marked the second consecutive quarter of positive adjusted EBITDA, which reached $6.7 million, driven by strong performance at the Gevo North Dakota facility and RNG facility.
Analyst Amit Dayal highlighted that Gevo, Inc.’s (NASDAQ:GEVO) Q3 2025 results prove its robust revenue stream and the company’s focus on effective carbon monetization. He also highlighted the extension of the Department of Energy’s $1.6 billion Conditional Commitment as a positive development for the company. He added that this will allow the company to explore various paths to market its aviation fuel capacity.
Gevo, Inc. (NASDAQ:GEVO) is a diversified energy company focused on carbon abatement through three main segments, including Gevo, GevoFuels, and GevoRNG.
7. The Real Brokerage Inc. (NASDAQ:REAX)
Market Capitalization: $769.97 million
Year-over-year Revenue Growth: 65.60%
3-Year Revenue Growth: 75.40%
Number of Hedge Fund Holders: 17
Analyst Upside Potential: 62.16%
The Real Brokerage Inc. (NASDAQ:REAX) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 6, William Blair analyst Stephen Sheldon reiterated a Buy rating on The Real Brokerage Inc. (NASDAQ:REAX) without disclosing any price targets.
This follows the analyst’s earlier Buy rating on the stock, which came after the company’s fiscal Q3 2025 results, announced on October 30. The company grew its revenue by 52.64% year-over-year to $568.55 million, surpassing analysts’ expectations by $34.75 million. The EPS of $0.00 also topped the consensus by $0.01. Management attributed the growth to a 50% increase in closed transactions, which was supported by a record number of agents on the platform.
Sheldon noted that The Real Brokerage Inc. (NASDAQ:REAX) delivered an impressive increase in attendance, followed by significant year-over-year growth in agent count and gross profit. The company ended the quarter with 30,100 agents, up 39% year-over-year, and the gross profit grew 40% during the same time to $45 million. In addition, the analyst also highlighted the company’s recent RISE conference, where it unveiled an advanced AI solution for agents. Sheldon believes that this solution can further bolster the company’s competitive edge.
The Real Brokerage Inc. is a software-driven real estate brokerage operating across the U.S. and parts of Canada. It uses AI and automation through its proprietary platform, reZEN, to improve agent productivity and offer seamless, flexible services.
6. CorMedix Inc. (NASDAQ:CRMD)
Market Capitalization: $885.59 million
Year-over-year Revenue Growth: 1647.67%
3-Year Revenue Growth: 1225.11%
Number of Hedge Fund Holders: 29
Analyst Upside Potential: 77.94%
CorMedix Inc. (NASDAQ:CRMD) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 13, H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and raised the price target from $17 to $18. The improved positive outlook follows the company’s earnings beat during its fiscal Q3 2025.
CorMedix Inc. (NASDAQ:CRMD) released fiscal Q3 2025 results on November 12. The revenue for the quarter grew 810.21% year-over-year to $104.28 million, surpassing estimates by $18.25 million. Moreover, the EPS of $1.26 also topped the consensus by $0.63. Revenue growth was largely driven by higher-than-expected utilization of DefenCath by the company’s outpatient dialysis customers, contributing $88.8 million to the net revenue.
Taking confidence from the results, CorMedix Inc. (NASDAQ:CRMD) raised its full-year pro forma net revenue guidance to a range of $390 to $410 million, and fourth-quarter net revenue guidance to a range of $115 to $135 million.
Analyst Folkes noted that the robust financial results were bolstered by the recent acquisition of Melinta, which has helped the company diversify its business. Moreover, the company’s pipeline also presents significant growth catalysts, including anticipated results from the Rezzayo study and the TPN Phase 3 data for DefenCath.
CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company focused on developing and commercializing therapeutic products to prevent and treat life-threatening infectious and inflammatory diseases.
5. Ardelyx, Inc. (NASDAQ:ARDX)
Market Capitalization: $1.42 billion
Year-over-year Revenue Growth: 58.12%
3-Year Revenue Growth: 253.58%
Number of Hedge Fund Holders: 27
Analyst Upside Potential: 87.71%
Ardelyx, Inc. (NASDAQ:ARDX) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 10, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) with a $14 price target. However, earlier on November 4, Allison Bratzel from Piper Sandler raised the firm’s price target on the stock from $9 to $10, while keeping a Hold rating on the stock.
The ratings follow the company’s fiscal Q3 2025, released on October 30, where the company topped estimates. The revenue grew 12.3% year-over-year to $110.33 million, surpassing estimates by $9.78 million. The EPS of $0.00 also topped estimates by $0.07. Management attributed revenue growth to a 92% year-over-year growth in IBSRELA revenue, which reached $78.2 million, surpassing the company’s estimates by $7 million. Management noted that the outperformance of IBSRELA is driven by sustained demand for a differentiated treatment option by IBS-C patients. Therefore, the company raised IBSRELA guidance and expects 2025 revenue to be between $270 million and $275 million.
Bratzel from Piper Sandler noted the growth in IBSERLA proves the company’s sales force strength. However, the firm awaits formal evidence of Xphozah’s near- and immediate-term outlook to formulate a more constructive opinion on Ardelyx, Inc. (NASDAQ:ARDX).
Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that develops and commercializes first-in-class medicines for gastrointestinal and kidney-related diseases.
4. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Market Capitalization: $1.66 billion
Year-over-year Revenue Growth: 50.07%
3-Year Revenue Growth: 69.69%
Number of Hedge Fund Holders: 26
Analyst Upside Potential: 102.09%
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 10, Matthew O’Brien from Piper Sandler reiterated a Buy rating on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) with a price target of $50. This follows the analyst’s earlier price target reduction from $55 to $50, and a Buy rating on November 4.
The price target was reduced despite the company exceeding expectations in its fiscal Q3 2025 results announced on November 4. PROCEPT BioRobotics Corporation (NASDAQ:PRCT) grew its revenue by 42.76% to $83.33 million, surpassing estimates by $2.56 million. Moreover, the EPS of negative $0.38 also topped the consensus by $0.04. Management attributed the revenue growth to strong demand for its HYDROS Robotic System, which grew 43% year-over-year, followed by a growing adoption of Aquablation therapy.
Analyst Matthew O’Brien noted that the company’s Q3 performance was better than expected, and the 2025 and 2026 sales forecasts are also close to Wall Street’s expectations. However, he highlighted that the bears will focus on soft utilization performance and investor destocking. Regardless, the analyst believes these issues to be temporary, caused by some internal changes in the company. The firm anticipates these changes to reap positive results for the company.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) develops and sells the AQUABEAM Robotic System, which is a surgical robot that uses real-time imaging and a heat-free water jet to precisely remove prostate tissue.
3. Astrana Health, Inc. (NASDAQ:ASTH)
Market Capitalization: $1.08 billion
Year-over-year Revenue Growth: 68.17%
3-Year Revenue Growth: 40.47%
Number of Hedge Fund Holders: 13
Analyst Upside Potential: 109.01%
Astrana Health, Inc. (NASDAQ:ASTH) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. Wall Street has a mixed opinion on Astrana Health, Inc. (NASDAQ:ASTH). On November 12, Jaliendra Singh from Truist Financial reiterated a Buy rating on the stock with a price target of $37. However, earlier on November 10, Ryan Langston from TD Cowen lowered the price target on the stock from $40 to $35, while keeping a Buy rating.
The mixed outlook follows the company’s fiscal Q3 2025 results, announced on November 6. The revenue grew 99.71% year-over-year to $956.05 million, surpassing estimates by $3.22 million. However, the EPS of $0.01 fell short of the consensus by $0.43. Management attributed the growth to being driven by the integration of Prospect Health into the company, followed by solid organizational growth across its core business.
However, looking ahead, management is expecting headwinds in its Medicaid and exchange business. Therefore, Astrana Health, Inc. (NASDAQ:ASTH) lowered its full-year revenue guidance to a range of $3.1 billion and $3.18 billion, down from the previous range of $3.1 billion to $3.3 billion. The Adjusted EBITDA guidance was also lowered to a range of $200 million and $210 million from the previous range of $215 million and $225 million.
The analyst Ryan Langston of TD Cowen noted that this reduced outlook reflects caution on Medicaid and the VBC environment.
Astrana Health, Inc. (NASDAQ:ASTH) is a physician-centered, technology-powered healthcare company that focuses on delivering coordinated, high-quality care to patients through its network of providers.
2. Sezzle Inc. (NASDAQ:SEZL)
Market Capitalization: $1.78 billion
Year-over-year Revenue Growth: 88.74%
3-Year Revenue Growth: 51.57%
Number of Hedge Fund Holders: 30
Analyst Upside Potential: 134.94%
Sezzle Inc. (NASDAQ:SEZL) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 6, Hoang Nguyen from TD Cowen lowered the firm’s price target on the stock from $86 to $83 and maintained a Hold rating. On the same day, Rayan Kumar from Oppenheimer also lowered the price target on Sezzle Inc. (NASDAQ:SEZL) from $134 to $110, but maintained a Buy rating on the stock.
The ratings follow the company’s fiscal Q3 2025, announced on November 5, 2025. The company grew its revenue by 66.95% year-over-year to $116.8 million, surpassing estimates by $12.09 million. The EPS of $0.71 also came ahead of the expectations by $0.06. The growth was driven by record high GMV of $1 billion, reflecting 58.7% year-over-year growth. Management attributed GMV growth to greater usage of subscription products and the company’s strategic focus on consumer acquisition, engagement, and retention.
In addition, Sezzle Inc. (NASDAQ:SEZL) also increased its EPS and Adjusted EBITDA guidance. The EPS guidance was raised from $3.25 to $3.38, and the Adjusted EBITDA guidance was raised from a range of $170 million – $175 million to $175 million – $180 million.
Sezzle Inc. (NASDAQ:SEZL) is a fintech company that offers a “buy now, pay later” payment platform, allowing consumers to split purchases into four interest-free installments.
1. Delcath Systems, Inc. (NASDAQ:DCTH)
Market Capitalization: $315.35 million
Year-over-year Revenue Growth: 251.54%
3-Year Revenue Growth: 166.87%
Number of Hedge Fund Holders: 21
Analyst Upside Potential: 157.56%
Delcath Systems, Inc. (NASDAQ:DCTH) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 5, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Delcath Systems, Inc. (NASDAQ:DCTH), but lowered the price target from $31 to $30.
Earlier on November 4, Delcath Systems, Inc. (NASDAQ:DCTH) released results for its fiscal Q3 2025. The company posted a revenue of $20.6 million, up from $11.2 million last year. Moreover, the EPS came in at $0.02, ahead of the consensus by $0.08. Management attributed revenue growth to HEPZATO KIT and CHEMOSAT revenues. The HEPZATO KIT revenue grew to $19.3 million from $10 million year-over-year, and CHEMOSAT revenue increased from $1.2 million in Q3 2024 to $1.3 million in the latest quarter. Notably, the gross margins also improved from 85% to 87% during the same time.
However, despite the strong performance, management lowered the full-year revenue guidance and now expects it to be in the range of $83 million to $85 million, down from the previous range of $93 million to $96 million. Management noted that this is due to a slowdown in new patient starts, partially due to summer seasonality.
Delcath Systems, Inc. (NASDAQ:DCTH) is a healthcare company specializing in interventional oncology treatments for liver cancers. Its main products include the HEPZATO KIT and CHEMOSAT Hepatic Delivery System.
While we acknowledge the potential of DCTH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DCTH and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
